Skip Navigation Links
A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed With Parkinson's Disease
Overall Recruitment Status: Active, currently enrolling
 
Official Title
A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed With Parkinson's Disease
 
Region Sponsors
California - Northern
CereGate Inc.
 
Acronym NCT No.
NCT05292794
 
Study Type Phase
INTERVENTIONAL
Phase I
 
Purpose
A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.
 
Detailed Description
This is a multi-center, controlled, study in which participants diagnosed with Parkinson's Disease (PD) and previously implanted with a subthalamic nucleus deep brain stimulation (STN-DBS) System will be assessed prior to initiation of CereGate (CG) therapy, and during CereGate therapy. No randomization will occur in this study. Participants will complete a total of five study visits (2 Screening Visits, Initiation Visit, day 60 follow-up and day 61 follow-up). The expected duration of participation in the clinical study is up to 104 days for each subject. Up to 41 participants diagnosed with PD previously implanted with a compatible STN-DBS System will be enrolled at up to five (5) sites in the United States. A maximum of 15 subjects may be enrolled at any site.
 
 
 
Inclusion Criteria
  • Participant has implanted Boston Scientific Gevia STN-DBS system
  • Participant is receiving treatment with carbidopa/levodopa, and/or with a dopamine agonist at the optimal doses as determined by a movement disorders neurologist
  • DBS optimized with documented improvement in motor signs (UPDRSIII) from DBS
 
Exclusion Criteria
  • Participant is unable to understand the study requirements and the treatment procedures, or unwilling / unable to provide written informed consent before any study-specific tests or procedures are performed
  • Participant is unwilling or unable to comply with visit schedule and study related procedures
  • Participant's medication regimen has not been stable for at least 28 days prior to CG initiation
  • Participant's DBS stimulation settings have not been stable for at least 28 days prior to CG initiation
  • Participant is less than 21 years of age or older than 75 years of age
  • Participant is a female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception as determined by the study investigator
  • Participant has a terminal illness with life expectancy of \< 1 year.
  • Participant has history of recurrent or unprovoked seizures.
  • Participant currently diagnosed with drug or alcohol abuse, per DSM-5 criteria.
  • Participant is in a very advanced stage of Parkinson's disease defined as: (i) Stage 5 as classified by the Hoehn and Yahr scale on medication and DBS (non-ambulatory) or (ii) participant requires an assistive device to perform the TBC OFF-meds /ON-DBS at the time of enrollment.
  • Participant has a condition that makes walking difficult or could interfere with the study procedures or confound the evaluation of the study data, including musculoskeletal issues, peripheral neuropathies, hip/knee prostheses, or any visual or anatomical abnormality that affects their walking.
  • Participant has disabling dyskinesias.
  • Participant has a history of suicide attempt or current active suicidal ideation as determined by a positive response to Items 2-5 of suicide ideation sub-scale of the Columbia Suicide Severity Rating Scale (CSSRS).
  • Participant, at the time of enrollment, fails the subthalamic nucleus (STN) stimulation challenge test (subject must perceive distinct bilateral sensations).
  • Participant has less than 8% arrhythmicity as measured in the Turning and Barrier Course Figures of 8 (TBC-F8) pre-CG therapy (ON Medications/ON DBS /OFF CG). Please contact study team for additional exclusion criteria
 
Keywords and/or Specific Medical Conditions
  • Basal Ganglia Diseases
  • Neurodegenerative Diseases
  • Brain Diseases
  • Parkinson Disease
  • Central Nervous System Diseases
  • Parkinsonian Disorders
  • CG-001
  • Synucleinopathies
  • Movement Disorders
  • Neurology (Neurological Disorders)
  • Nervous System Diseases
 
KP Clinical Facility
  • Redwood City Medical Center
 
Clinical Area
  • Neurology/Neurological Disorders


Principal Investigator:
Elena Call, MD
Contact Information:
- CTP Collaborate Team
-CTPCollaborate@kp.org
-Redwood City Medical Center


smilelady1
Do you want to receive
Email Alerts?

Sign Up Here!